All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubAML HubGVhD HubMDS HubMPN HubMultiple Myeloma

How do you decide between continuous or time-limited therapy for CLL?

During the ESH Translational Research Conference, the Lymphoma Hub was pleased to speak with Anthony Mato, Memorial Sloan Kettering Cancer Center, New York, US. We asked, How do you decide between continuous or time-limited therapy for CLL?

How do you decide between continuous or time-limited therapy for CLL?

Mato begins by outlining the current continuous treatment approaches, as well as next-generation agents acalabrutinib and zanubrutinib. Mato goes on to discuss venetoclax combinations as time-limited approaches, and the lack of long-term data on venetoclax compared with BTK inhibitors. Finally, Mato discusses how the decision between continuous or long-term approaches should take the individual patient into consideration.

Share: